ES2543166T3 - Composiciones y métodos para modular la actividad de proteínas reguladoras del complemento sobre células diana - Google Patents

Composiciones y métodos para modular la actividad de proteínas reguladoras del complemento sobre células diana Download PDF

Info

Publication number
ES2543166T3
ES2543166T3 ES10764877.6T ES10764877T ES2543166T3 ES 2543166 T3 ES2543166 T3 ES 2543166T3 ES 10764877 T ES10764877 T ES 10764877T ES 2543166 T3 ES2543166 T3 ES 2543166T3
Authority
ES
Spain
Prior art keywords
seq
domain
polypeptide
fiber
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10764877.6T
Other languages
English (en)
Spanish (es)
Inventor
Andre Lieber
Hongjie Wang
Ronald Jay Berenson
Darrick Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Compliment Corp
Original Assignee
University of Washington
Compliment Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Compliment Corp filed Critical University of Washington
Application granted granted Critical
Publication of ES2543166T3 publication Critical patent/ES2543166T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10764877.6T 2009-03-31 2010-03-31 Composiciones y métodos para modular la actividad de proteínas reguladoras del complemento sobre células diana Active ES2543166T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US165434P 1999-11-15
US16543409P 2009-03-31 2009-03-31
US25545009P 2009-10-27 2009-10-27
US255450P 2009-10-27
PCT/US2010/029471 WO2010120541A2 (fr) 2009-03-31 2010-03-31 Compositions et méthodes de modulation de l'activité des protéines régulatrices du complément sur des cellules cibles

Publications (1)

Publication Number Publication Date
ES2543166T3 true ES2543166T3 (es) 2015-08-17

Family

ID=42826361

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10764877.6T Active ES2543166T3 (es) 2009-03-31 2010-03-31 Composiciones y métodos para modular la actividad de proteínas reguladoras del complemento sobre células diana

Country Status (5)

Country Link
US (1) US8753639B2 (fr)
EP (1) EP2414385B1 (fr)
CN (1) CN102448982B (fr)
ES (1) ES2543166T3 (fr)
WO (1) WO2010120541A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1998804B1 (fr) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprenant un adénovirus recombiné et un adjuvant
EP2611464B1 (fr) 2010-09-03 2018-04-25 AbbVie Stemcentrx LLC Nouveaux modulateurs et leurs procédés d'utilisation
WO2014194213A1 (fr) * 2013-05-30 2014-12-04 University Of Iowa Research Foundation Protéines de complément spécifiques et efficacité d'une thérapie par les anticorps
CN107405411A (zh) * 2014-05-01 2017-11-28 华盛顿大学 使用腺病毒载体的体内基因改造
CA2966551A1 (fr) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Dosage et procede permettant de determiner des anticorps induisant la cdc
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
WO2017216098A1 (fr) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Dosage et procédé de détermination d'anticorps induisant la cdc
WO2018232195A1 (fr) * 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions et procédés ciblant le composant 3 du complément pour inhiber la croissance tumorale
US20220257796A1 (en) 2019-07-02 2022-08-18 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
CN117805382B (zh) * 2024-02-28 2024-05-03 军科正源（北京）药物研究有限责任公司 检测抗利妥昔单抗中和抗体的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7390795B2 (en) * 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
US20040002060A1 (en) * 2002-01-24 2004-01-01 Novartis Ag Fiber shaft modifications for efficient targeting
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
EP1931803A2 (fr) 2005-09-15 2008-06-18 Duke University Banques ciblees, profilage fonctionnel, laser selex et deselex

Also Published As

Publication number Publication date
WO2010120541A2 (fr) 2010-10-21
WO2010120541A3 (fr) 2011-05-26
CN102448982B (zh) 2018-04-20
US20100255011A1 (en) 2010-10-07
EP2414385B1 (fr) 2015-04-22
EP2414385A4 (fr) 2012-11-28
EP2414385A2 (fr) 2012-02-08
US8753639B2 (en) 2014-06-17
CN102448982A (zh) 2012-05-09

Similar Documents

Publication Publication Date Title
ES2543166T3 (es) Composiciones y métodos para modular la actividad de proteínas reguladoras del complemento sobre células diana
ES2582340T3 (es) Métodos para manipular fagocitosis mediada por CD47
US10577406B2 (en) FKBP-L polypeptides and uses in angiogenesis-mediated disorders
ES2808153T3 (es) Terapia de combinación para tratamiento de enfermedad
ES2363765T3 (es) Agonistas de fgfr.
JP2022023184A (ja) アクチビン－ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
ES2845184T3 (es) Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
ES2696000T3 (es) Receptores de antígenos quiméricos anti-variante III de receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
CN107683289B (zh) IL13Rα2结合剂和其在癌症治疗中的用途
ES2928111T3 (es) Inhibición de la señalización AXL en terapia antimetastásica
ES2649165T3 (es) CD47 terapias dirigidas para el tratamiento de enfermedades infecciosas
US12031137B2 (en) Compositions comprising SASP modulators and senescence attenuators and uses thereof for modulating cellular senescence
ES2647568T3 (es) Tratamiento de cáncer
CN112512559A (zh) 用于治疗nrp2相关疾病的组合物和方法
US11339209B2 (en) Compositions, methods, and therapeutic uses related to fusogenic protein minion
JP2012529891A (ja) ミオチューブラリン１（ｍｔｍ１）ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物
CN110300603A (zh) Cd47-car-t细胞
ES2862335T3 (es) Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
US20210163598A1 (en) Tumor immunotherapy target and application thereof
ES2645366T3 (es) Tratamiento de trastornos de la angiogénesis
JP2021536256A (ja) 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
AU2016250354A1 (en) Activin-ActRII antagonists and uses for increasing red blood cell levels
TWI609692B (zh) 新穎ｓｔｉｐ１多肽及其用途
ES2940360T3 (es) Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1
JP5102630B2 (ja) 改変パラミクソウイルスおよびその作製方法